Moussa Faminini, MD
Endocrinology, Diabetes & Metabolism · Encino, CANPI 1629084843
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 489 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 52 manufacturers, the largest accounting for just 14.6% — the pattern of someone who eats at a lot of different presentations.
Across 489 payments — averaging $35.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- AbbVie$2K
- AstraZeneca$2K
- Novo Nordisk$1K
- Johnson & Johnson$1K
- GSK$907
- plus $7K from 46 others
What the payments were for
- Speaking & faculty fees$901%
- Food & beverage$17,24599%
- Education$1511%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,487 in reported general payments places this provider in the 85th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 253 | $229,203 |
| FarxigaDapagliflozin Propanediol | 231 | $169,263 |
| LinzessLinaclotide | 185 | $151,781 |
| OzempicSemaglutide | 111 | $126,221 |
| TrulicityDulaglutide | 93 | $122,624 |
| EliquisApixaban | 145 | $107,533 |
| JanuviaSitagliptin Phosphate | 102 | $100,623 |
| MounjaroTirzepatide | 94 | $96,043 |
| ZenpepLipase/Protease/Amylase | 68 | $83,812 |
| VascepaIcosapent Ethyl | 186 | $79,580 |
| Metformin Er GastricMetformin Hcl | 24 | $64,690 |
| MyrbetriqMirabegron | 78 | $50,349 |
| XareltoRivaroxaban | 45 | $40,313 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 64 | $39,167 |
| ProliaDenosumab | 24 | $38,479 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $460 | $279,795305 claims |
| AbbVieLinzess, Creon, Namzaric, Restasis, Synthroid | $1,989 | $230,241336 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $336 | $218,667187 claims |
| AstraZenecaFarxiga | $1,974 | $169,263231 claims |
| MerckJanuvia, Janumet, Janumet Xr | $178 | $132,666162 claims |
| Novo NordiskOzempic | $1,451 | $126,221111 claims |
| PfizerEliquis | $272 | $107,533145 claims |
| Aimmune Therapeutics, Inc.Zenpep | $80 | $83,81268 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $907 | $66,610129 claims |
| Astellas Pharma US IncMyrbetriq | $266 | $50,34978 claims |
| Johnson & JohnsonXarelto | $1,445 | $40,31345 claims |
| AmgenProlia | $2,545 | $38,47924 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Encino
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
- Daniel Einhornla Jolla$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.